Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR94-/-, and MyD884-/- mice

被引：0
|
作者：
Wang, Daqing [1 ]
Tao, Lan [1 ]
Tang, Jimmy [1 ]
Kandimalla, Ekambar [1 ]
Agrawal, Sudhir [1 ]
机构：
[1] Idera Pharmaceut Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5067
引用
收藏
页数：1
相关论文
共 8 条
  • [1] Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR9-/-, and MyD88-/- mice
    Wang, Daqing
    Tao, Lan
    Tang, Jimmy
    Kandimalla, Ekambar
    Agrawal, Sudhir
    CANCER RESEARCH, 2009, 69
  • [2] Antitumor activity of a dual agonist of TLR7 and TLR8 in combination with bevacizumab in preclinical models of human non-small cell lung and colon cancers
    Wang, Daqing
    Lan, Tao
    Tang, Jimmy
    Kandimalla, Ekambar
    Agrawal, Sudhir
    CANCER RESEARCH, 2009, 69
  • [3] IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies
    Wang, Daqing
    Precopio, Melissa
    Reardon, Michael J.
    Lan, Tao
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Bexon, Alice
    La Monica, Nicola
    Agrawal, Sudhir
    BLOOD, 2011, 118 (21) : 1591 - 1591
  • [4] Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies
    Wang, D.
    Precopio, M.
    Reardon, M.
    Lan, T.
    Tang, J. X.
    Kandimalla, E. R.
    Bexon, A. S.
    La Monica, N.
    Agrawal, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
    Wang, Daqing
    Precopio, Melissa
    Reardon, Michael
    Lan, Tao
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    La Monica, Nicola
    Agrawal, Sudhir
    BLOOD, 2010, 116 (21) : 188 - 188
  • [6] Preclinical antitumor activity of the TLR7/8 agonist vesatilomod combined with the HDAC inhibitor romidepsin as a new therapeutic concept for the treatment of colorectal carcinoma
    Strumberg, D.
    Asif, R. H.
    Acikelli, A. H.
    Noa-Bolano, A.
    D'Souza, F.
    Klein, J.
    Diaz-Carballo, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 313 - 313
  • [7] MEDI 217-Novel heterocyclic TLR7 and TLR8 immune response modifiers: Design and synthesis of cytokine-inducing 2H-pyrazolo[3,4-c]quinolin-4-amines
    Hays, David S.
    Danielson, Michael E.
    Haraldson, Chad A.
    Niwas, Shri
    Gerster, John F.
    Bonk, Jason D.
    Mackey, Sonja J.
    Lindstrom, Kyle J.
    Prince, Ryan B.
    Moseman, Joan T.
    Lundquist, Gregory D.
    Kavanagh, Maureen A.
    Kshirsagar, Tushar A.
    Heppner, Philip D.
    Moser, William H.
    Rice, Michael J.
    Wurst, Joshua R.
    Spessard, Sarah J.
    Radmer, Matthew R.
    Strong, Sarah A.
    Amos, David T.
    Willie, Daniel J.
    Wurst, Lindsay R.
    Gibson, Sheila J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [8] A NOVEL IMMUNOSTIMULATORY TLR7/8 AGONIST IS CURATIVE AS A MONOTHERAPY IN LEWIS LUNG CARCINOMA AND SYNERGIZES WITH ANTI-PD-1 IN B16F10 AND MC38 TUMOR MODELS
    Miller, Shannon
    Beyer, Caleb
    Talbot, Danielle
    Jackson, Konner
    Whitacre, Margaret
    Ward, Janine
    Schoener, Roman
    Bazin, Helene
    Burkhart, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1211 - A1211
1